SCHEMBL31000736

SCHEMBL31000736

COC(=O)c1cc2nc(C)cc(Cl)n2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.43
▸ KDM4E B2RXH2 8/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ HPGD P15428 3/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ GAA P10253 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ ATM Q13315 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ MAPK1 P28482 2/20 0.36
▸ TSHR P16473 2/20 0.36
▸ F2 P00734 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ MITF O75030 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ AKT1 P31749 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL4776618 0.87 KDM4E (0.41) ALDH1A1KDM4EKMT2AHPGDMEN1
SCHEMBL24930956 0.83 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDSMN1; SMN2GAA
SCHEMBL20840130 0.79 KDM4E (0.42) ALDH1A1KDM4EKMT2AHPGDMEN1
SCHEMBL4776497 0.77 MAPT (0.44) ALDH1A1KDM4EKMT2AHPGDMEN1
SCHEMBL29893250 0.71 KMT2A (0.45) ALDH1A1KDM4EKMT2AMEN1L3MBTL1
SCHEMBL20840115 0.71 ATR (0.40) ALDH1A1KDM4EHPGDTDP1
SCHEMBL12838092 0.71 NPC1 (0.43) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL4726693 0.71 ALDH1A1 (0.37) ALDH1A1KDM4EGAA
SCHEMBL7066666 0.70 RAB9A (0.51) ALDH1A1KDM4EKMT2AHPGDMEN1
SCHEMBL5204247 0.69 KDM4E (0.61) ALDH1A1KDM4EKMT2AHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. 2024-11-14 — — US disclosed
CN-118401507-A Inhibitors targeting ubiquitin-specific protease 7 (USP 7) 丹娜法伯癌症研究院 2024-07-26 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) USP7, USP47, USP2 ALDH1A1 2692/4885KDM4E 1617/4885KMT2A 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback